Trial Information

Summary: Do you suffer from gout?

Objective of the study is to assess the efficacy and safety of Febuxostat 40 mg QD and Febuxostat 80 mg QD, compared to Allopurinol in subjects with hyperuricemia and gout. The study's duration is 6 months long.

Patient Inclusion Criteria

  • Male or female (18 to 85 years of age)
  • History or presence of gout

Patient Exclusion Criteria

  • Received ULT within 30 days of randomizing
  • History of cancer, other than basal cell, within 5 years
  • Rheumatoid arthritis requiring treatment

For more information,

Contact:

Health Research Institute
1044 SW 44th Street
Suite 403
Oklahoma City, OK 73109
Telephone: 405-616-4888
Fax: 405-616-4885
Email:

Profile Page: Health Research Institute, Oklahoma City, OK

If you would like to learn more about participating in this study, please send an e-mail message using the form below.

*Subject:

Name:

Address:

City:

State:

*Zip:

*Country:

Phone:

*Email address:

Message:

Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 6:30:14 AM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA